title: Neutralization of interleukin-17 attenuates high fat diet-induced non-alcoholic fatty liver disease in mice.
abstract: Non-alcoholic fatty liver disease (NAFLD) is hepatic manifestation of a metabolic syndrome and includes a spectrum of hepatic steatosis, steatohepatitis, and fibrosis. Interleukin-17 (IL-17) has been reported to play a critical role in inflammatory progression of some liver diseases. The present study was designed to investigate the role of IL-17 on high fat diet-induced NAFLD in C57BL/6 mice. IL-17 blockade with anti-IL-17mAb signiﬁcantly improved liver function, attenuated hepatic lipid accumulation, suppressed Kuffer cells activation, and decreased pro-inflammatory cytokines levels, which were associated with inhibition of NF-κB signaling cascades activation. Our data suggested that IL-17 was related to disease progression in NAFLD mouse model and blocking IL-17 may be a promising novel therapeutic approach for patients with NAFLD.
authors.affiliation: Department of Endocrinology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
authors.forename: Renfan
authors.initials: R
authors.lastname: Xu
authors.forename: Anyu
authors.initials: A
authors.lastname: Tao
authors.forename: Shasha
authors.initials: S
authors.lastname: Zhang
authors.forename: Muxun
authors.initials: M
authors.lastname: Zhang
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology*; D000943:Antigens, Differentiation / Q000235:genetics / Q000378:metabolism; D015153:Blotting, Western; D059305:Diet, High-Fat / Q000009:adverse effects; D004195:Disease Models, Animal; D005234:Fatty Liver / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D015870:Gene Expression / Q000187:drug effects; D006801:Humans; D018836:Inflammation Mediators / Q000097:blood; D020381:Interleukin-17 / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000276:immunology; D015850:Interleukin-6 / Q000097:blood / Q000235:genetics; D008099:Liver / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D016328:NF-kappa B / Q000378:metabolism; D065626:Non-alcoholic Fatty Liver Disease; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015398:Signal Transduction / Q000187:drug effects; D014280:Triglycerides / Q000378:metabolism
chemical_list: D000911:Antibodies, Monoclonal; D000943:Antigens, Differentiation; D018836:Inflammation Mediators; D020381:Interleukin-17; D015850:Interleukin-6; D016328:NF-kappa B; D014280:Triglycerides; C036763:monocyte-macrophage differentiation antigen
keywords: IL-17mAb; NF-κB; non-alcoholic fatty liver disease